• About
  • EPISEEK
  • Solutions
    • Firefighters
  • Resources
    • News
  • Contact
  • Download Test Order Form
Order Tests Now
Precision Epigenomics and Front Line Mobile Health to Deliver EPISEEK Cancer Testing to First Responders in TX, CO, & GA

Precision Epigenomics and Front Line Mobile Health to Deliver EPISEEK Cancer Testing to First Responders in TX, CO, & GA

by Amy Cook | Dec 10, 2025 | Industry, News

Exclusive Partnership to Deliver EPISEEK® Cancer Screening Blood Test in Texas, Colorado, & Georgia. View the press release here.  Tucson, AZ, — Precision Epigenomics, a leader in epigenetic-based cancer detection, today announced an exclusive partnership with...
2024 Flinn Foundation Bioscience Entrepreneurship Program Partner

2024 Flinn Foundation Bioscience Entrepreneurship Program Partner

by pesbm | Apr 2, 2024 | Industry

Precision Epigenomics Inc. announced today that it was selected by…
USPTO Patent for Precision Epigenomics

USPTO Patent for Precision Epigenomics

by pesbm | Jan 24, 2024 | Industry

Precision Epigenomics Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Molecular Diagnostic Technology
National Human Genome Research Training Grant

National Human Genome Research Training Grant

by pesbm-sam | Jan 20, 2024 | Industry

Precision Epigenomics Inc. and Arizona State University collaborators are awarded a training grant by National Human Genome Research Institute to train students in bioinformatics through the Training in Genomics Research program
National Cancer Center $397,000 Grant

National Cancer Center $397,000 Grant

by pesbm-sam | Feb 1, 2022 | Industry

The National Cancer Institute awards $397,000 grant to Precision Epigenomics
Arizona Research Day Highlight

Arizona Research Day Highlight

by pesbm-sam | Apr 14, 2021 | Industry

Precision Epigenomics is highlighted at University of Arizona Research Day
« Older Entries

Recent Posts

  • Precision Epigenomics and Front Line Mobile Health to Deliver EPISEEK Cancer Testing to First Responders in TX, CO, & GA
  • New Clinical Test Developed to Accurately Classify Pleural Effusions
  • Precision Epigenomics: Tactical Steps in Multi-Cancer Early Detection and Beyond
  • Precision Epigenomics Joins the Conversation: Key Takeaways from Rosetta Fest
  • Precision Epigenomics Named “Startup of the Year” by University of Arizona, Honored for Pioneering Early Cancer Detection Technology

Recent Comments

No comments to show.
The EPISEEK® test is recommended for use in adults with an elevated risk for cancer, such as those aged 45 or older. The EPISEEK test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. EPISEEK is intended to detect cancer signals. Use of EPISEEK is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected does not completely rule out cancer. A test result of Abnormal Methylation Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm or exclude the presence of cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present (i.e. EPISEEK false positive) or confirmatory testing was insufficient to detect a very early cancer (follow up testing false negative). False positive (abnormal methylation signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Quick Links

Home
About
Tests
Resources
News
Contact

Other Pages

Privacy Policy
Terms & Conditions
FCOI

Contact Info



630 N Alvernon Way
Ste 280B
Tucson, AZ 85711



520.372.7522



520.777.7367

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow